Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Gelenis Domingo"'
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 6, Iss 1, Pp e2014068-e2014068 (2014)
Abstract Background Escherichia coli (E. coli) is a pathogen of great concern in immunosuppressed patients. While antimicrobial prophylactic therapy has become the standard, the emergence of resistant pathogens has some questioning its use. This st
Externí odkaz:
https://doaj.org/article/8013003daab44d4294c4d3b6ff957428
Publikováno v:
Expert review of respiratory medicine. 14(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::91527c2ea5f2dfc0eee97cfe6a74c3d6
https://pubmed.ncbi.nlm.nih.gov/31971859
https://pubmed.ncbi.nlm.nih.gov/31971859
Autor:
Jennifer Cudris, Edgardo S. Santos, Gelenis Domingo, Michel Velez, Cesar A. Perez, Luis E. Raez
Publikováno v:
Expert Review of Anticancer Therapy. 10:1577-1587
Lung cancer research has incorporated molecular medicine into the management of this disease during the last 5 years. Several novel tumorigenesis pathways associated with lung cancer development and proliferation have been discovered and further deve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40837e835c96e0e13b7fcafbb0cd16fb
https://doi.org/10.1586/era.10.141
https://doi.org/10.1586/era.10.141
Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC
Autor:
Michel Velez, Astrid Belalcazar, Luis E. Raez, Gelenis Domingo, Edgardo S. Santos, Marcelo Blaya
Publikováno v:
Expert Review of Anticancer Therapy. 10:549-557
For many decades, the use of chemotherapy as second-line therapy in non-small-cell lung cancer relied upon disease progression. Several studies have shown that four to six cycles of chemotherapy administered as front-line therapy treatment offers a s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23ef387a9fb6d6e481ee57899320961a
https://doi.org/10.1586/era.10.30
https://doi.org/10.1586/era.10.30
Publikováno v:
Leukemialymphoma. 52(5)
Relapsed/refractory acute myeloid leukemia (AML) is associated with a poor prognosis and a median overall survival of less than 1 year [1]. Allogeneic hematopoietic stem cell transplant (HSCT) rema...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57089811cdbd47850fdaa49df875e8f2
https://pubmed.ncbi.nlm.nih.gov/21417821
https://pubmed.ncbi.nlm.nih.gov/21417821